Alpha Cognition reports Q4 revenue of $2.5M for Alzheimer’s drug

Alpha Cognition reported Q4 2025 net product revenue for ZUNVEYL of $2.5M and full-year 2025 total revenue of $10.2M. FY2025 net loss widened to $20.7M (vs $14.8M in 2024) with operating loss of $22.7M and SG&A rising to $29.1M; diluted LTM EPS was -$1.33. Cash and equivalents were $66.0M at year-end (up from $48.5M), the company completed a $40M net capital raise in Oct 2025 and expects ~2 years of runway, targeting operating profitability in 2027. Commercial traction includes Q4 bottles dispensed of 4,941 (+62% QoQ) and a 50% QoQ increase in prescribers; the company also secured a U.S. patent covering dosing methods through July 2045 and granted executive equity awards.

Analysis

Alpha Cognition’s early commercial traction sits on a knife edge: one or two additional PBM wins will produce non-linear Rx growth in the long‑term care (LTC) channel because formulary access there converts high-concentration prescribers quickly. Conversely, the remaining PBM holdouts and typical LTC rebate mechanics mean headline gross margin (currently high) can compress materially as volumes scale and mandatory rebates kick in; expect realized margins to drift lower by 800–1,200bps if aggressive payer contracting is required.

The new patent is a defense but not impregnable: it’s for dosing methods rather than composition, which raises the probability of design‑around generics or alternate formulations (e.g., sublingual generics or compounded equivalents) entering the market later in the 2030s despite a 2045 nominal term. The sublingual program is a true optionality — positive Phase 1/2 signals in 2026 would expand addressable scenarios in LTC (patients with swallowing issues) and materially re-rate the commercial multiple.

Financially, the ~two‑year runway creates a clear timebox for commercial proof points; management can either deplete cash to accelerate uptake (higher short‑term dilution risk) or pace investment and hit 2027 operating-profitability guidance only with sustained adoption. Key near‑term catalysts to watch: additional PBM contracts, CONVERGE real‑world readouts, RESOLVE enrollment milestones, and regulatory/payer coverage updates; immediate downside triggers are slower-than-expected bottle growth, larger-than-forecast SG&A burn, or an adverse PBM formulary decision.

Key Decisions for Investors

• Long ACOG (ACOG) — buy shares with a 12–18 month horizon to capture PBM wins and sublingual development optionality. Target 40–80% upside if ACOG secures a 3rd PBM and quarterly bottles continue >50% q/q; size position modestly (2–5% of liquid biotech allocation) and hedge with 9–12 month protective puts ~25–30% OTM to limit downside to single‑digit portfolio impact.
• Options structured trade — purchase ACOG Jan‑2028 LEAP calls and sell near‑dated (90–120 day) calls to finance ~50–60% of premium. Rationale: long-dated calls capture multi‑milestone optionality (PBMs, RESOLVE, sublingual), while sold short calls monetize near-term time decay if uptake stalls; monitor IV and roll if implied vol spikes on trial news.
• Pair trade (event‑driven) — long ACOG / short Alzheon (ALZ) equal dollar, 12 months. Thesis: ACOG’s commercial runway and immediate PBM optionality are underpriced versus ALZ’s single‑asset clinical risk; reduce net exposure on third PBM win or CONVERGE positive signal. Set stop losses at 25% for each leg.
• Event entry sizing and exit rules — initiate a small starter position now, add materially only after a 3rd PBM contract or positive interim RESOLVE/CONVERGE readout. Take 50% profits on either (a) sustained sequential quarter bottle growth >40% q/q for two quarters or (b) an announced pathway reducing payer barriers; exit or tighten hedges if cash runway drops below 12 months or SG&A overruns increase by >50% vs plan.